NCT00397241

24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations

24-hour IOP With DTFC and LTFC Monotherapies and the Adjunctive Therapy of DTFC and Latanoprost in Open-angle Glaucoma Insufficiently Controlled With Latanoprost Monotherapy.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: Aristotle University Of Thessaloniki · Academic / Other
• Sex: All
• Age: 29 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this crossover trial is to compare the 3-month mean 24-hour intraocular pressure (IOP) control and safety of dorzolamide/timolol fixed combination (DTFC) given twice daily, versus latanoprost/timolol fixed combination (LTFC) given in the evening and placebo given in the morning, versus adjunctive therapy with DTFC given twice daily and latanoprost 0.005% given once in the evening in open-angle glaucoma patients who are insufficiently controlled with latanoprost monotherapy.

Conditions

• Open-angle Glaucoma

Interventions

Type	Name	Description
DRUG	Drug: dorzolamide/timolol
DRUG	Drug: latanoprost/timolol
DRUG	dorzolamide/timolol and latanoprost
DRUG	placebo (artificial tears)

Timeline

• Start date: 2006-09-01
• Primary completion: 2007-12-01
• Completion: 2007-12-01
• First posted: 2006-11-08
• Last updated: 2020-12-19

Locations

1 site across 1 country: Greece